Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 06, 2026
Why Is Barrett Business Services (BBSI) Stock Down -20.84% Today?

Why Is Barrett Business Services (BBSI) Stock Down -20.84% Today?

Key Takeaways

  • BBSI shares plunged 20.84% on Thursday, falling to $31.75 from a prior close of $40.11, in one of the stock's worst single-day performances in years.
  • The primary catalyst was a second-quarter earnings miss and a downward revision to full-year guidance, with EPS of $0.52 falling short of the $0.56 consensus and the company trimming the high end of its gross billings and worksite employee growth forecasts.
  • Roth Capital downgraded the stock to Neutral from Buy, slashing its price target from $42 to $38, citing persistent margin pressure and challenging market fundamentals.
  • Workers' compensation cost headwinds and soft client hiring trends compounded the bearish narrative, with management characterizing 2026 as a "transition year" and a low point for gross margins.
  • Traders are now watching for stabilization around technical support levels and any signs of improving client hiring trends or margin recovery in the second half of the year.

Opening Summary

BBSI, the professional employer organization (PEO) and business management solutions provider officially known as Barrett Business Services, Inc., suffered a dramatic sell-off on Thursday as investors absorbed the fallout from disappointing second-quarter earnings and a cautious outlook revision. The stock closed the session at $31.75, down $8.36 — a decline of 20.84% from Wednesday's closing price of $40.11. The steep drop marks the most severe single-day reaction to an earnings report for the Vancouver, Washington-based company in recent memory, driven by an EPS miss, reduced guidance, and a subsequent analyst downgrade.

Earnings Miss and Guidance Cut Spark the Sell-Off

Barrett Business Services reported second-quarter results after the closing bell on Wednesday, and the numbers fell short on multiple fronts. GAAP earnings per share came in at $0.52, missing the analyst consensus estimate of $0.56 by $0.04. Revenue grew 3.8% year over year to $319.3 million, but that also came in slightly below the $322.15 million Wall Street was expecting. The bottom-line deterioration was notable: net income dropped to $12.9 million from $18.5 million in the same quarter a year ago, as higher workers' compensation costs and reduced favorable prior-year claims adjustments weighed on profitability.

More troubling for investors was the company's revised outlook. Management narrowed its full-year 2026 guidance across several key metrics. Gross billings growth is now expected at 3% to 4%, down from the prior range of 3% to 5%. Average worksite employee growth was trimmed to 2% to 3% from 2% to 4%. Gross margin as a percentage of gross billings was tightened to 2.70% to 2.75%, versus the previous 2.70% to 2.85%. CEO Gary Kramer pointed to "continued softness in client hiring" as the primary growth headwind, noting that workforce reductions at existing clients partially offset strong new client acquisition, which rose 17% year over year.

Analyst Downgrade Amplifies Bearish Sentiment

Adding fuel to the sell-off, Roth Capital downgraded BBSI to Neutral from Buy and cut its price target to $38 from $42. The firm cited "challenging market fundamentals" that would limit near-term upside, and reduced its own estimates to reflect what it described as modest reductions in gross billings and growth guidance. Roth emphasized that margin pressure is expected to persist through the end of 2026, a view that aligns with management's own characterization of the year as a transition period before anticipated improvement in 2027.

Workers' Compensation and Margin Headwinds

A key structural challenge weighing on BBSI is the evolving workers' compensation pricing environment in California, its largest market. Favorable prior-year liability and premium adjustments totaled just $2.0 million in the second quarter, down sharply from $8.8 million a year earlier — a decline management attributed to industrywide increases in claim-cost expectations. While the company has been raising workers' compensation pricing for eight consecutive months and the California Insurance Commissioner has approved cumulative rate increases, the benefit of higher pricing compounds gradually because clients renew monthly. Kramer noted that higher litigation and cumulative trauma claims, including post-termination claims, have contributed to the market shift. Operating margin contracted to 4.8% from 7.5% in the year-ago quarter, underscoring the near-term profitability pressure.

Market Context and Trading Activity

The magnitude of Thursday's decline placed BBSI among the sharpest movers in the professional staffing and HR solutions space. The move was decidedly company-specific rather than sector-driven; peers in the PEO and staffing industry did not experience comparable sell-offs. The stock's elevated volume confirmed strong conviction behind the move. BBSI shares had been trading near $40 — roughly in line with their recent range — before the earnings release, meaning the gap lower broke through several weeks of price consolidation. At $31.75, the stock is now trading at levels not seen since early 2026, well below its 52-week high near $49 achieved in September 2025.

What Comes Next for BBSI

The road ahead for BBSI hinges on several factors. Management has framed 2026 as the trough for gross margins, with improvement expected in 2027 as cumulative pricing actions on workers' compensation build through additional client renewals. Investors will be closely watching monthly worksite employee data for signs that client hiring is stabilizing or recovering. The company's strong balance sheet — $67.9 million in unrestricted cash and no debt — provides a cushion, and its ongoing capital return program, including $15 million in stock repurchases during the second quarter at an average price of $30.92, signals management's confidence in long-term value. However, risks remain: if macroeconomic uncertainty persists and client hiring continues to lag, the recovery timeline could extend further. The company's next quarterly update, along with any signs of improvement in the East Coast and asset-light markets that have shown stronger growth, will be critical for restoring investor confidence.

Trending AI Robots

For traders seeking to navigate volatile market conditions with data-driven strategies, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers across diverse strategies, timeframes, and performance benchmarks — but only the strongest performers under current market conditions are featured in this regularly updated section. Whether you favor momentum-based approaches, swing trading, or longer-term trend-following strategies, exploring the Trending AI Robots can help you discover automated trading tools aligned with today's market dynamics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BBSI

BBSI sees its Stochastic Oscillator recovers from oversold territory

On August 04, 2026, the Stochastic Oscillator for BBSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 54 instances where the indicator left the oversold zone. In of the 54 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on BBSI as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBSI advanced for three days, in of 338 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 254 cases where BBSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BBSI moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for BBSI turned negative on July 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBSI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BBSI broke above its upper Bollinger Band on July 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BBSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.771) is normal, around the industry mean (4.975). P/E Ratio (26.118) is within average values for comparable stocks, (26.104). Projected Growth (PEG Ratio) (1.759) is also within normal values, averaging (2.212). BBSI has a moderately low Dividend Yield (0.008) as compared to the industry average of (0.032). P/S Ratio (0.826) is also within normal values, averaging (0.829).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

Industry description

Other consumer services include companies that provide consumer services, and are not classified elsewhere. Travel fare aggregators, hotel bookings, consumer-to-consumer or business-to-business sales platforms are some examples of services that can be clubbed into this category. Many of such services have expanded online. Booking Holdings Inc, The Priceline Group Inc, and eBay Inc. are some major operators in this segment.

Market Cap

The average market capitalization across the Other Consumer Services Industry is 1.18B. The market cap for tickers in the group ranges from 16 to 18.76B. CTRP holds the highest valuation in this group at 18.76B. The lowest valued company is STAFQ at 16.

High and low price notable news

The average weekly price growth across all stocks in the Other Consumer Services Industry was 5%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 14%. TBI experienced the highest price growth at 33%, while HQI experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Other Consumer Services Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 36
P/E Growth Rating: 55
Price Growth Rating: 46
SMR Rating: 83
Profit Risk Rating: 93
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
BBSI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of human resources management services

Industry OtherConsumerServices

Profile
Details
Industry
Personnel Services
Address
8100 NE Parkway Drive
Phone
+1 360 828-0700
Employees
3197
Web
https://www.bbsi.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Why Is Barrett Business Services (BBSI) Stock Down -20.84% Today?